CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

1

A CSF proteomics study identified a 22-protein panel that enhances MS diagnosis, especially in patients without classical biomarkers.
2

The research utilized high-throughput mass spectrometry to analyze approximately 1,500 proteins per CSF sample from over 5,000 individuals.
3

Machine-learning analysis distinguished MS from other inflammatory diseases, improving diagnostic accuracy in challenging cases.
4

The identified proteins reflect MS pathology, including B-cell activity and axonal damage, and may provide prognostic information.
5

The methodology established could be applied to other neurological conditions lacking reliable molecular markers.

1